Alerta

CELLS FOR TREATMENT AND/OR PREVENTION OF SARS-COV-2 INFECTION AND PRODUCTION METHOD THEREFOR

Resumen de: WO2026018922A1

The purpose of the present disclosure is to provide highly versatile, ready-to-deliver allogenic T cells for novel coronavirus infection, and a production method therefor. The present invention provides: a method for producing a cell population for the treatment and/or prevention of SARS-CoV-2 infection and including T cells or precursor T cells that express a human T cell receptor (TCR) specific to SARS-CoV-2, said method comprising a step for causing the expression of one or more human TCRs specific to SARS-CoV-2 in T cells or precursor T cells in vitro; and a cell population for the treatment and/or prevention of SARS-CoV-2 infection and produced via said method, said cell population comprising allogenically derived T cells or precursor T cells.

PEPTIDES WITH ANTIVIRAL ACTIVITY

Resumen de: WO2026019338A1

The invention relates to organic chemistry, pharmacology and medicine and concerns novel antiviral peptides. The claimed peptides are characterized by a high level of antiviral activity and show promise for use in the treatment of infectious diseases caused by a viral infection, inter alia, diseases caused by SARS-CoV-2 such as, for example, a simple infection (such as a fever, a cough and/or a sore throat), pneumonia, acute or severe respiratory infection, hypoxic respiratory failure, acute respiratory distress syndrome, sepsis or septic shock and, in particular, COVID-19.

SYSTEMS AND METHODS FOR SEQUENCE DESIGN

Resumen de: EP4682890A2

A messenger RNA (mRNA) vaccine has emerged as a promising direction to combat the COVID-19 pandemic. This requires an mRNA sequence that is stable and highly productive in protein expression, features to benefit from greater mRNA secondary structure folding stability and optimal codon usage. Sequence design remains challenging due to the exponentially many synonymous mRNA sequences encoding the same protein. The present disclosure presents embodiments of a linear-time approximation (LinearDesign) reducing the design to an intersection between a Stochastic Context Free Grammar (SCFG) and a Deterministic Finite Automaton (DFA). Embodiments of the LinearDesign may implement an mRNA sequence design using much reduced time with very limited loss. Various methodologies, e.g., finding alternative sequences based on k-best parsing or directly incorporating codon optimality, are presented for incorporating the codon optimality into the design. Embodiments of the LinearDesign may provide efficient computational tools to speed up and improve mRNA vaccine development.

PROTEIN AND VACCINE AGAINST INFECTIONS OF SARS-COV-2 OMICRON MUTANT STRAIN XBB AND SUBTYPE THEREOF

Resumen de: EP4682160A1

The present invention relates to a protein and a vaccine against infections by a SARS-CoV-2 Omicron variant XBB and subvariants thereof, which belongs to the medicine field. To address the lack of effective prophylactic and therapeutic agents against the infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof, the present invention provides proteins and vaccines against infections by the variants, the vaccines are designed based on the full-length S protein, the receptor-binding domain (RBD) sequence and optimized sequences of SARS-CoV-2 Omicron variant XBB and subvariant XBB.1.5, thereof, which are are capable of aiding the host in combating coronavirus infections, and particularly have a relatively good preventive and therapeutic effect against cross-infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof.

Coronavirus S protein mutant and application thereof

Resumen de: CN121342933A

The invention discloses a coronavirus S protein mutant and application thereof. The invention provides a coronavirus S protein mutant, the S protein mutant is a mutant having mutation in a conserved region in a cytoplasm tail region of a wild type S protein, and the mutation is that the fourth amino acid in the conserved region is mutated into leucine. According to the present invention, the fourth amino acid in the conserved region in the cytoplasm tail region of the S protein is mutated into the leucine, and the mutation is introduced into the vaccine of SARS-CoV-2, SARS-CoV, MERS-CoV and other viruses so as to significantly enhance the immunogenicity.

GRNA library targeting SARS-CoV-2 virus positive strand and negative strand subgenomes

Nº publicación: CN121344787A 16/01/2026

Solicitante:

UNIV SUN YAT SEN
\u4E2D\u5C71\u5927\u5B66

Resumen de: CN121344787A

The invention belongs to the technical field of gene engineering, and relates to a gRNA library of a targeted SARS-CoV-2 virus subgenome. The library is obtained through multi-step rational design screening, is composed of 65 gRNAs, can specifically recognize and target positive chain and negative chain subgenome RNAs of viruses ORF3a, E, M, ORF6, ORF7a, ORF7b, ORF8, N and ORF10, and has a sequence as shown in SEQ ID NO: 1 to 65. The gRNA can form a CRISPR-Cas13b (clustered regularly interspaced short palindromic repeats-associated protein 13b) system with a Cas13b protein, and is used for non-therapeutically inhibiting the replication of the SARS-CoV-2 virus.